LncRNA USP2-AS1 Promotes Hepatocellular Carcinoma Growth by Enhancing YBX1-Mediated HIF1α Protein Translation Under Hypoxia

被引:8
作者
Chen, Shi-Ping [1 ]
Zhu, Gui-Qi [1 ]
Xing, Xiao-Xia [2 ,3 ]
Wan, Jing-Lei [2 ]
Cai, Jia-Liang [2 ]
Du, Jun-Xian [4 ]
Song, Li-Na [2 ]
Dai, Zhi [2 ,3 ]
Zhou, Jian [1 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg & Transplantat, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China
[3] Fudan Univ, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
TME; tumor microenvironment; USP2-AS1; ubiquitin specific peptidase 2 antisense RNA 1; YBX1; Y-box binding protein 1; lncRNA; HIF1; alpha; Lenvatinib; hypoxia; HCC; LONG NONCODING RNA; CANCER; RESISTANCE; ACTIVATION; HIF-1-ALPHA; MECHANISMS; EXPRESSION; SORAFENIB;
D O I
10.3389/fonc.2022.882372
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, the role of lncRNAs in tumorigenesis and development has received increasing attention, but the mechanism underlying lncRNAs-mediated tumor growth in the hypoxic microenvironment of solid tumors remains obscure. Using RNA sequencing, 25 hypoxia-related lncRNAs were found to be upregulated in HCC, of which lncRNA USP2-AS1 were significantly increased under hypoxia. We further confirmed that USP2-AS1 was significantly upregulated in liver cancer using FISH assay and that USP2-AS1 was associated with advanced liver cancer and increased tumor size. Furthermore, overexpression of USP2-AS1 under hypoxia dramatically increased HCC proliferation and clone formation, whereas the opposite results were observed after USP2-AS1 knockdown. We also found that overexpression of USP2-AS1 increased migration and invasion of HCC cells, while USP2-AS1 knockdown led to the opposite effect. In addition, USP2-AS1 knockdown can increase the efficacy of lenvatinib in our mice tumor xenograft model. Our findings also suggest that USP2-AS1 could increase the protein level of HIF1 alpha by enhancing YBX1 protein binding to HIF1 alpha mRNA under hypoxia and the therapeutic effect of lenvatinib can be enhanced by combination with HIF1 alpha inhibitors in liver cancer.
引用
收藏
页数:12
相关论文
共 48 条
  • [11] PLAGL2-EGFR-HIF-1/2α Signaling Loop Promotes HCC Progression and Erlotinib Insensitivity
    Hu, Weiwei
    Zheng, Shufang
    Guo, Haixin
    Dai, Beiying
    Ni, Jiaping
    Shi, Yaohong
    Bian, Hanrui
    Li, Lanxin
    Shen, Yumeng
    Wu, Mo
    Tian, Zhoutong
    Liu, Guilai
    Hossain, Md Amir
    Yang, Hongbao
    Wang, Duowei
    Zhang, Qin
    Yu, Jun
    Birnbaumer, Lutz
    Feng, Jifeng
    Yu, Decai
    Yang, Yong
    [J]. HEPATOLOGY, 2021, 73 (02) : 674 - 691
  • [12] The emerging role of IncRNAs in cancer
    Huarte, Maite
    [J]. NATURE MEDICINE, 2015, 21 (11) : 1253 - 1261
  • [13] PERK/eIF2α signaling inhibits HIF-induced gene expression during the unfolded protein response via YB1-dependent regulation of HIF1α translation
    Ivanova, Iglika G.
    Park, Catherine V.
    Yemm, Adrian I.
    Kenneth, Niall S.
    [J]. NUCLEIC ACIDS RESEARCH, 2018, 46 (08) : 3878 - 3890
  • [14] Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
    Jain, Rakesh K.
    [J]. CANCER CELL, 2014, 26 (05) : 605 - 622
  • [15] EGFR activation limits the response of liver cancer to lenvatinib
    Jin, Haojie
    Shi, Yaoping
    Lv, Yuanyuan
    Yuan, Shengxian
    Ramirez, Christel F. A.
    Lieftink, Cor
    Wang, Liqin
    Wang, Siying
    Wang, Cun
    Dias, Matheus Henrique
    Jochems, Fleur
    Yang, Yuan
    Bosma, Astrid
    Hijmans, E. Marielle
    de Groot, Marnix H. P.
    Vegna, Serena
    Cui, Dan
    Zhou, Yangyang
    Ling, Jing
    Wang, Hui
    Guo, Yuchen
    Zheng, Xingling
    Isima, Nikita
    Wu, Haiqiu
    Sun, Chong
    Beijersbergen, Roderick L.
    Akkari, Leila
    Zhou, Weiping
    Zhai, Bo
    Qin, Wenxin
    Bernards, Rene
    [J]. NATURE, 2021, 595 (7869) : 730 - +
  • [16] Role of hypoxia in cancer therapy by regulating the tumor microenvironment
    Jing, Xinming
    Yang, Fengming
    Shao, Chuchu
    Wei, Ke
    Xie, Mengyan
    Shen, Hua
    Shu, Yongqian
    [J]. MOLECULAR CANCER, 2019, 18 (01)
  • [17] Activation of hypoxia-inducible factor 1 alpha: Posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor
    Kallio, PJ
    Pongratz, I
    Gradin, K
    McGuire, J
    Poellinger, L
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (11) : 5667 - 5672
  • [18] Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Piscaglia, Fabio
    Baron, Ari
    Park, Joong-Won
    Han, Guohong
    Jassem, Jacek
    Blanc, Jean Frederic
    Vogel, Arndt
    Komov, Dmitry
    Evans, T. R. Jeffry
    Lopez, Carlos
    Dutcus, Corina
    Guo, Matthew
    Saito, Kenichi
    Kraljevic, Silvija
    Tamai, Toshiyuki
    Ren, Min
    Cheng, Ann-Lii
    [J]. LANCET, 2018, 391 (10126) : 1163 - 1173
  • [19] Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma
    Liang, Chao
    Dong, Zhebin
    Cai, Xianlei
    Shen, Jie
    Xu, Yuan
    Zhang, Miaozun
    Li, Hong
    Yu, Weiming
    Chen, Wei
    [J]. CELL DEATH & DISEASE, 2020, 11 (11)
  • [20] HSP90α Mediates Sorafenib Resistance in Human Hepatocellular Carcinoma by Necroptosis Inhibition under Hypoxia
    Liao, Yan
    Yang, Yue
    Pan, Di
    Ding, Youxiang
    Zhang, Heng
    Ye, Yuting
    Li, Jia
    Zhao, Li
    [J]. CANCERS, 2021, 13 (02) : 1 - 21